|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author, year** | **Study design1** | **Start year of enrollment / Length of followup** | **Location / Multicenter** | **Adherence reported / Adherence >80% in each study arm** | **Inclusion criteria** |
| Myrelid, 2006189 | Prospective cohort | Start year: 1989Median followup duration: 84.7 months | EuropeSingle center | NA | CD only, previous surgery , previous use of azathioprine or 6-MP, other criteria |
| Reinisch, 2010188 | RCT, parallel arms | Start year: 2002Duration of assigned treatment: 52 weeks | Europe, AsiaMulticenter | YesNo | Adults, CD only, previous surgery (resection of terminal ileum and partial colectomy with ileoclonic anastomosis), CDAI (<200), in remission for >1 weeks, no use of antibiotics, TNF-alpha inhibitors, corticosteroids, immunomodulators, NSAIDs other than paracetamol or low-dose aspirin, moderate-severe disease, no short bowel syndrome, smokers and non smokers, other criteria |

Abbreviations: 6-MP = 6-mercaptopurine; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; NA = not applicable; NSAID = non-steroidal anti-inflammatory drug; RCT = randomized controlled trial; TNF = tumor necrosis factor